An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size. Several other ligands, including GDF11 and the activins, signal through this pathway, suggesting that the ActRII receptors are major regulatory nodes in the regulation of muscle mass. We have developed a novel, human anti-ActRII antibody (bimagrumab, or BYM338) to prevent binding of ligands to the receptors and thus inhibit downstream signaling. BYM338 enhances differentiation of primary human skeletal myoblasts and counteracts the inhibition of differentiation induced by myostatin or activin A. BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation. BYM338 dramatically increases skeletal muscle mass in mice, beyond sole inhibition of myostatin, detected by comparing the antibody with a myostatin inhibitor. A mouse version of the antibody induces enhanced muscle hypertrophy in myostatin mutant mice, further confirming a beneficial effect on muscle growth beyond myostatin inhibition alone through blockade of ActRII ligands. BYM338 protects muscles from glucocorticoid-induced atrophy and weakness via prevention of muscle and tetanic force losses. These data highlight the compelling therapeutic potential of BYM338 for the treatment of skeletal muscle atrophy and weakness in multiple settings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“blocking these receptors can result in profound muscle growth in animals and humans18–22”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [19]
In the citing paper
“Interestingly, STC2 is among the genes that are downregulated in skeletal muscle from mice following bimagrumab (activin type II receptor antagonist) treatment [149].”
From Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting (2023) · cites this paper as [149]
In the citing paper
“Myostatin is secreted by the myocytes and inhibits their differentiation and proliferation.”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
In the citing paper
“Myostatin and Activin receptor type 2 (ActRII) inhibitors have been developed and shown to increase muscle mass and strength and as well as improve insulin sensitivity in vitro (94, 95).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
In the citing paper
“Its level increased in individuals with sarcopenia and/or obesity.”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752 · cited 1×
“This restoration of AKT phosphorylation is important, since AKT has been shown in prior studies to be required for weight-bearing-induced skeletal muscle hypertrophy; we have also previously shown that AKT activates mTOR-mediated phosphorylation of p70S6 kinase in skeletal muscle (49) and inhibits GSK3, resulting in m…”
BackgroundSelf-citationDouble muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 1×
“In addition to myostatin (5, 6), other negative regulators of muscle mass have been reported to signal through ActRIIB, including activin A (10–13), while some uncertainty with regard to the contribution of the closely related GDF11 at regulating muscle mass and function remains (13–15).”
BackgroundRegulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 3×
“Prior studies had suggested this as well (10, 18), but this is the first demonstration that an antibody directed at the ActRII receptor can induce significantly greater hypertrophy than myostatin inhibition alone; the point had been made with the ActRIIB trap, but that molecule can actually also bind other ligands tha…”
BackgroundRommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583 · cited 1×
“This restoration of AKT phosphorylation is important, since AKT has been shown in prior studies to be required for weight-bearing-induced skeletal muscle hypertrophy; we have also previously shown that AKT activates mTOR-mediated phosphorylation of p70S6 kinase in skeletal muscle (49) and inhibits GSK3, resulting in m…”
BackgroundSelf-citationMyostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Clop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940 · cited 3×
“Intervention at the ActRIIB pathway level under cancer cachexia conditions in mice showed a clear benefit not only for muscle preservation but also for overall survival, without affecting tumor growth (24).”
BackgroundInduction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002) · Science · doi:10.1126/science.1069525 · Cited by 907
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826
Research works printed but not linked: 1
- Glass D, 2010, Curr. Top. Microbiol. Immunol., 346, 267
Cited by
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
GDF11 increases with age and inhibits skeletal muscle regeneration
Egerman, M. A., Cadena, S. M., Gilbert, J. A., Meyer, A., Nelson, H. N., Swalley, S. E., Mallozzi, C., Jacobi, C., Jennings, L. L., Clay, I., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.010 · Cited by 527
“Even though we demonstrated similar direct signaling of GDF11 and myostatin and that this correlated to inhibitory effects by both molecules on the differentiation of human skeletal myoblasts, it was still formally possible that GDF11 might have some unique activity on muscle, distinct from its activation of ActRII/AL…”
InfluentialSelf-citationMechanisms of metabolic dysfunction in cancer-associated cachexia
Petruzzelli, M., & Wagner, E. F. (2016) · Genes & Development · doi:10.1101/gad.276733.115 · Cited by 340
“Furthermore, inhibition of ActRIIB by a humanized monoclonal antibody has been shown to increase skeletal muscle mass and prevent glucocorticoid-induced atrophy in mice (Lach-Trifilieff et al. 2014).”
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338
Cancer cachexia: molecular mechanisms and treatment strategies
Setiawan, T., Sari, I. N., Wijaya, Y. T., Julianto, N. M., Muhammad, J. A., Lee, H., Chae, J. H., & Kwon, H. Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01454-0 · Cited by 315
“The clinical trial of another inhibitor, such as BYM338, which specifically inhibits myostatin and activin A, has been tested in a phase II clinical trial (NCT01925209, 2013), and GDF11 is now being considered in clinical trials [263, 270].”
Background
Metadata
- Authors
- Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., Hatakeyama, S., & Glass, D. J.
- Affiliations
- MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Novartis (Switzerland) (CH)
- Development and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA
- Novartis Institutes for BioMedical Research (CH)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2014-02-01
- Volume
- 34
- Issue
- 4
- Pages
- 606-618
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC3911487
- OpenAlex
- W2102107385
- Semantic Scholar
- 9ec58206f235e018d6953a27e975ae19a1c51271
- Cited by
- 306
- References
- 58
- Citations by year
- 2026: 22 · 2025: 16 · 2024: 19 · 2023: 21 · 2022: 20 · 2021: 37 · 2020: 29 · 2019: 28 · 2018: 25 · 2017: 18 · 2016: 29 · 2015: 21 · 2014: 19
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis
- MorphoSys
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- activin type II receptor, bimagrumab, myostatin, skeletal muscle hypertrophy, muscle atrophy, Smad2/3 phosphorylation, skeletal myoblast differentiation, activin A, GDF11, muscle weakness, myosin heavy chain degradation, muscle mass regulation
- MeSH terms
- Animals, Antibodies, Monoclonal, Atrophy, Cell Differentiation, Humans, Hypertrophy, Signal Transduction, Muscle, Skeletal, Antibodies, Blocking, Activins, Activin Receptors, Type II, Myoblasts, Skeletal, Mice, Smad2 Protein, Smad3 Protein, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy. https://app.cochat.ai/papers/10.1128/mcb.01307-13
- The paper
- Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., Hatakeyama, S., & Glass, D. J. (2014). An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy. Molecular and Cellular Biology. https://doi.org/10.1128/mcb.01307-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.